Liam Ratcliffe was appointed Director of OnKure Therapeutics, Inc. As of November 6, 2026, OnKure Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 30, 2026 to August 13, 2026, naming 1 appointment (Form 8-K, March 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like OnKure Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
OnKure Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-30 to 2026-08-13. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as OnKure Therapeutics, Inc. files it.
Also on the record for OnKure Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G, by Coastlands Capital LP | 6.67% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by ADAR1 Capital Management, LLC | 5.5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Trails Edge Capital Partners, LP | 3.6% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13G/A, by Prosight Management, LP | 2.4% of the class | 5%+ stakes | Source |
| May 27, 2026 | Stake report, Schedule 13G, by BVF PARTNERS L P/IL | 5.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by ADAR1 Capital Management, LLC | 6% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13D, by AI Biotechnology LLC | 19.99% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G, by StepStone Group LP | 6.6% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G, by Trails Edge Capital Partners, LP | 6% of the class | 5%+ stakes | Source |
| April 1, 2026 | Stake report, Schedule 13G, by Anders Hove | 9.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs OnKure Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on OnKure Therapeutics, Inc. and the records around it.
OnKure Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- StepStone Group LP also filed stake reports on 2 other companies: StepStone Private Equity Strategies Fund (May 2026)
- AI Biotechnology LLC also filed stake reports on 3 other companies: Latigo Biotherapeutics, Inc. (Nov 2026), Yarrow Bioscience, Inc. (Jul 2026), Zura Bio Limited (Mar 2026)
- Cantor Fitzgerald Securities also filed stake reports on 3 other companies: Satellogic Inc. (Mar 2026), M3-Brigade Acquisition V Corp. (Mar 2026), Sono Group N.V. (Feb 2026)
Watch OnKure Therapeutics, Inc.
Get an email when OnKure Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on OnKure Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on OnKure Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on OnKure Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 21 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-13 | Reported | not named in the filing | 8-K, 2026-08-13 | ||
| 2026-03-30 | In | Director | 8-K, 2026-03-30 |
Who leads OnKure Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Liam Ratcliffe, appointed (filed 2026-03-30).
New leaders reset buying decisions — get the Full Report on OnKure Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at OnKure Therapeutics, Inc., with the record behind each one.
Find candidates like Director at OnKure Therapeutics, Inc.Every change, in the filing's words
Reported
The repricing generally applied to all outstanding and unexercised stock options to purchase shares of the Company's Class A common stock ("Shares") granted prior to January 1, 2025, under the Company's 2024 Equity Incentive Plan or the Company's 2021 Stock Incentive Plan (each, a "Plan"), with an exercise price per Share equal to or greater than $10.00, held by certain employees and consultants (such options, the "Eligible Options"), including each of the Company's named executive officers, as of the Effective Date.
- (e) Repricing of Certain Underwater Options On August 7, 2026 (the "Effective Date"), the Board of Directors (the "Board") of OnKure Therapeutics, Inc. (the "Company") approved an option repricing.
- The new exercise price per Share for repriced options is $4.14, the closing price of the Company's Class A common stock on the Effective Date.
- However, if the optionee exercises his or her repriced Eligible Option without achieving the retention requirement (as defined below), such optionee will be required to pay a premium exercise price that is equal to the original exercise price per Share of such Eligible Option.
- There were no changes made to any Eligible Options' term to expiration, vesting criteria, or underlying number of shares, and each repriced Eligible Option remains subject to the terms of the applicable Plan and award agreement.
- For purposes of the repricing, the retention requirement refers to the optionee being required to remain a service provider through (i) the date 18 months following the Effective Date, in the case of certain members of senior management including each of the Company's named executive officers, or (ii) the one-year anniversary of the Effective Date, in the case of other employees or service providers.
Appointed: Liam Ratcliffe, Director
On March 27, 2026, in connection with the Private Placement, the Board elected Dr. Liam Ratcliffe as a Class I director of the Company, effective and contingent on the closing of the Private Placement.
- Dr. Ratcliffe was elected to the Board pursuant to the director designation right granted to the Lead Investor pursuant to the Purchase Agreement.
- Dr. Ratcliffe has no familial relationships with any executive officer or director of the Company.
- Dr. Ratcliffe is affiliated with the Lead Investor.
Tools for this story
Each opens in a new tab, filled in for OnKure Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.